|
Cell line | Description | Histology | Origin | Mutation | Adherence | Method of implantation | Animal model/s | Cell inoculation | Percentage tumor take | Palpable tumours | Metastatic potential | References |
|
DMS-53 | Small-cell carcinoma | SCLC | Male, age 54, smoking status unknown | Low Ras activity, p53 mutation | Adherent | Subcutaneous, hind flank injection | Female BALB/c nude mice Female nude athymic | 10(6)–10(7) cells/mouse with PBS or matrigel | 50–100% | 4–8 weeks | Not previously described | [23, 24] |
|
NCI-H69 | Small-cell carcinoma | SCLC | Male, age 55, smoking status unknown | p53 deficient, wild type but low EGFR | Suspension, multicell aggregates | Subcutaneous, hind flank injection | Female athmyic nun/nu/CR hind flank | 5 × 10(6) cells/mouse with PBS or matrigel | 80–100% | 15 days–4 weeks | Not previously described | [25] |
|
A549 | Adenocarcinoma | NSCLC | Male, age 58, smoking status unknown | Ras mutation | Adherent | Subcutaneous, hind flank injection | BALB /cAnNCrlBR athymic (nu+/nu+) | 2 × 106–2 × 10(7) cells/mouse with matrigel | 100% | 2–5 weeks | Not previously described | [26–30] |
Endobronchial | BALB/c or NMRI-nu/nu female mice | 1 × 10(4)–1 × 10(6) cells/mouse | 90% | 9–61 days | Yes. Left lung, liver and spleen | [31] |
|
H1299 | Carcinoma | NSCLC | Male, age 43, smoking status unknown | N-Ras mutation, P53 negative High EGFR expression | Adherent | Subcutaneous, hind flank injection | Female athymic nude mice BALB/c nude mice | 2 × 106–1 × 107 cells/mouse with matrigel | 45–100% | 4–6 weeks | Not previously described | [27, 29, 32] |
|
NCI-H460 | Large cell carcinoma | NSCLC | Male, age and smoking status unknown | K-Ras mutation | Adherent | Subcutaneous, hind flank injection | Female athymic nude mice (Ncr nu/nu) | 3 × 10(5)–1 × 10(7) cells/mouse with matrigel | 100% | 4–11 days | Not previously described | [28, 31, 33–36] |
Endobronchial | Female athymic nude mice (Ncr nu/nu) | 1 × 10(4)–1 × 10(6) cells/mouse | 90% | 9–61 days | Yes. Left lung, liver and spleen | [31] |
|
H1975 | Adenocarcinoma | NSCLC | Female, non-smoker | EGFR mutation L858R and T790M | Adherent | Subcutaneous, hind flank injection | Female athymic (nu/nu) mice NMRI-nu/nu female mice | 1 × 10(6)–1 × 10(7) cells/mouse with matrigel | 50–100% | 4–8 weeks | Not previously described | [28, 37] |
|
NCI-H226 | Squamous carcinoma | NSCLC | Male, age and smoking status unknown | P53 mutation | Adherent | Subcutaneous, hind flank injection | BALB/c nude mice Female SCID/SCID mice | 8 × 106 cells/mouse with PBS or matrigel | 50–100% | 4–8 weeks | Not previously described | [36] |
|
HCC827 | Adenocarcinoma | NSCLC | Female, age 39, smoking status unknown | In-frame deletion (dE746-A750) in exon 19 of EGFR increased copy number | Adherent | Subcutaneous, hind flank injection | Female athymic (nu/nu) mice Female BALB/cA nude mice | 2 × 10(7) cells/mouse with matrigel | 80–100% | 4-5 weeks | Not previously described | [26, 28] |
|
HCC4006 | Adenocarcinoma | NSCLC | Male, age >50, smoking status unknown | In-frame deletion (dE746-A750) in exon 19 of EGFR | Adherent | Subcutaneous, hind flank injection | Female SCID/SCID mice | 1-2 × 106 cells/mouse with PBS or matrigel | 50–100% | 4–8 weeks | Not previously described | [38] |
|
NCI-H358 | Bronchioalviolar carcinoma | NSCLC | Male, age and smoking status unknown | Wild-type EGFR | Adherent | Subcutaneous, hind flank injection | Female athymic (nu/nu) mice | 2 × 107 cells/mouse with PBS or matrigel | 100% | 4-5 weeks | Not previously described | [26, 28, 39] |
|
LLC | Lewis lung carcinoma | NSCLC | C57BL mouse | Not reported | Mixed, adherent and suspension | Subcutaneous, leg injection | Male C57BL mice | 2 × 106 cells/mouse | 100% | 7 days | Yes. Lung | [40] |
|
NCI-H23 | Adenocarcinoma | NSCLC | Male, 51 years | p53 mutation | Adherent | Subcutaneous | Female BALB-C nude mice | 3 × 3 × 3 mm tumor fragment | 100% | 14 days | Not previously described | [36] |
|
DMS-273 | Small-cell carcinoma | SCLC | Female, 50 years | p53 mutation | Adherent | Subcutaneous | Female BALB-C nude mice | 3 × 3 × 3 mm tumor fragment | 100% | 14 days | Not previously described | [36] |
|
DMS-114 | Small-cell carcinoma | SCLC | Male, 68 years | p53 mutation | Adherent | Subcutaneous | Female BALB-C nude mice | 3 × 3 × 3 mm tumor fragment | 100% | 14 days | Not previously described | [36] |
|
TL-1 | Squamous carcinoma | NSCLC | Not reported | Not reported | Adherent | Subcutaneous | CB-17 scid/scid mice | 2 × 106 cells/mouse in saline | 60–70% | 3-4 weeks | Not previously described | [41] |
|
NCI-H526 | Carcinoma | SCLC | Male, 55 years | KIT positive | Suspension | Subcutaneous, hind flank injection | Female athymic nu/nu mice | 5 × 106 cells/mouse in saline | 100% | 20 days | Not previously described | [42] |
|
NCI H82 | Carcinoma | SCLC | Male, 40 years | KIT negative | Suspension | Subcutaneous, hind flank injection | Female athymic nu/nu mice | 5 × 106 cells/mouse in saline | 100% | 25 days | Not previously described | [42] |
|
NCI-H358 | Bronchioalviolar carcinoma | NSCLC | Male | Wt EGFR Mutated ras | Adherent | Subcutaneous, hind flank injection | Female athymic nu/nu mice | 2 × 107 cells/mouse with 1 : 1 PBS and matrigel | 100% | Not reported | Not previously described | [28] |
|